Condensed Consolidated Interim Statements of Comprehensive Loss (Unaudited) - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2022 |
Jun. 30, 2021 |
Jun. 30, 2022 |
Jun. 30, 2021 |
|
| OPERATING EXPENSES | ||||
| Wages and salaries | $ 1,359,503 | $ 169,300 | $ 2,148,144 | $ 338,965 |
| Consulting | 1,145,323 | 181,651 | 1,508,418 | 491,596 |
| Professional fees | 780,331 | 108,343 | 881,400 | 253,251 |
| Office and administrative | 317,152 | 51,288 | 630,890 | 112,275 |
| Investor and public relations | 261,435 | 88,249 | 606,924 | 165,086 |
| Research and development | 30,329 | 31,277 | 426,856 | 61,260 |
| Share based compensation | 56,390 | 65,559 | 214,372 | 155,801 |
| Lease expense | 78,498 | 5,092 | 159,435 | 7,286 |
| Travel and entertainment | 89,694 | 10,231 | 158,821 | 11,306 |
| Shareholder and regulatory | 37,684 | 1,037 | 146,663 | 3,345 |
| Sales and marketing | 59,757 | 90,382 | ||
| Depreciation | 5,465 | 2,728 | 8,992 | 5,323 |
| Operating loss | (4,221,561) | (714,755) | (6,981,297) | (1,605,494) |
| OTHER EXPENSES | ||||
| Foreign exchange loss (gain) | (103,472) | 5,609 | (38,964) | (524) |
| Change in fair value of warrants | (675,504) | (218,462) | ||
| Accretion of interest on senior secured debentures | 427,360 | 427,360 | ||
| Loss on extension of debt term | 59,259 | 59,259 | ||
| Net loss | (3,442,585) | (1,206,983) | (6,723,871) | (2,091,589) |
| Dividend paid to preferred shareholders | 532,258 | 532,258 | ||
| Net loss attributable to common shareholders | (3,442,585) | (1,739,241) | (6,723,871) | (2,623,847) |
| Other comprehensive income (loss) | ||||
| Foreign currency translation | (21,192) | (5,285) | (33,093) | 7,749 |
| Comprehensive loss attributable to common shareholders | $ (3,463,777) | $ (1,744,526) | $ (6,756,964) | $ (2,616,098) |
| Basic and diluted net loss attributed to common share | $ (0.21) | $ (0.20) | $ (0.43) | $ (0.30) |
| Weighted average number of common shares outstanding – basic and diluted | 16,518,480 | 8,892,989 | 15,872,349 | 8,668,881 |
| X | ||||||||||
- Definition Accretion of interest on senior secured debentures No definition available.
|
| X | ||||||||||
- Definition Consulting No definition available.
|
| X | ||||||||||
- Definition Investor And Public Relations No definition available.
|
| X | ||||||||||
- Definition Loss on extension of debt term No definition available.
|
| X | ||||||||||
- Definition Shareholder And Regulatory No definition available.
|
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line. No definition available.
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The aggregate total amount of expenses directly related to the marketing or selling of products or services. No definition available.
|
| X | ||||||||||
- Definition Amount of noncash expense for share-based payment arrangement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Expenses incurred for travel and entertainment during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|